OsteoFloxacin™
Prosthetic Joint Infection (PJI)
Key Facts
About BioVinc
BioVinc is a clinical-stage biotech pioneering a bone-selective drug delivery platform to address critical unmet needs in skeletal diseases, with an initial focus on prosthetic joint infections (PJI). The company's core technology utilizes bisphosphonate-based 'smart targeting' to concentrate therapeutics at the bone site, improving efficacy and reducing systemic side effects. Its lead program, OsteoFloxacin™, is an antibiotic conjugate in the pre-clinical/IND-enabling stage, positioned as a potential cure for PJI with eligibility for orphan drug designation. Founded in 2008 and built on decades of bisphosphonate research expertise, BioVinc is advancing a pipeline that could expand into other bone-related conditions, including cancer and arthritis.
View full company profileTherapeutic Areas
Other Prosthetic Joint Infection (PJI) Drugs
| Drug | Company | Phase |
|---|---|---|
| PLG0206 | Peptilogics | Phase 2/3 |